中国医药健康产业股份有限公司 关于公司涉及诉讼事项的进展公告

Group 1: Litigation Update - The company is currently involved in a lawsuit at the second instance stage, where it is the appellant [2] - The amount involved in the litigation is approximately 139.40 million yuan [2] - The company filed a civil lawsuit against Tibet Tiansheng Taifeng Pharmaceutical Co., Ltd. and Xu Panfeng due to a contract dispute related to performance compensation [3] Group 2: Progress of the Lawsuit - The company has appealed the first-instance judgment made by the Beijing Second Intermediate People's Court, and Tibet Tiansheng has also filed an appeal [4] Group 3: Impact on the Company - As of the date of the announcement, the second-instance hearing has not yet been scheduled, and the final outcome remains uncertain [5] Group 4: Drug Approval Announcement - The company's subsidiary, Hainan Tongyong Kangli Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for two injection formulations of Ganciclovir, which passed the consistency evaluation for generic drugs [8] - The drug is primarily used for treating life-threatening or vision-threatening cytomegalovirus infections in immunocompromised patients and for preventing such infections in organ transplant patients [9] Group 5: Financial and Market Information - The total investment in the drug amounts to approximately 3.94 million yuan (unaudited) [11] - The domestic sales of the drug in public hospitals and grassroots medical institutions were approximately 259 million yuan in 2024, although the subsidiary did not sell the drug in that year [12]